Cinacalcet exhibits a diverse range of bioactivities, including inhibitory effects on ROR gamma transcriptional activity, Histone Lysine Methyltransferase G9a, TGF-b, USP1/UAF1, human tyrosyl-DNA phosphodiesterase 1 (TDP1), and the malarial parasite plastid. It induces DNA re-replication in various cell types and modulates PINK1 expression, indicating broad biological effects. Notably, Cinacalcet acts as a positive allosteric modulator of the human Calcium-sensing receptor (CaSR) in CHO cells with an EC50 value of 80.0 nM, and potentiates human GlyR-alpha1 expressed in Xenopus laevis oocytes, showing an activity of 182.0% at 1 µM and a maximum activity of 210.0% at 10 µM. The compound also inhibits recombinant human P450 CYP2D6 enzyme with an IC50 value of 50.0 nM.
In terms of toxicity, Cinacalcet shows a lack of bioactivity in hepatic side effect assays, suggesting a low risk for drug-induced liver injury and related conditions. Furthermore, it demonstrates minimal efficacy against SARS-CoV-2, with weak inhibition of virus-induced cytotoxicity in VERO-6 cells and moderate inhibition of the SARS-CoV-2 3CL-Pro protease.
Cinacalcet also displays inhibitory activity against enzymes such as human HDAC6 and porcine heart malate dehydrogenase, with IC50 values of >20000 nM and 74,000 nM, respectively. Additionally, it shows antagonist activity at human HRH1 and CHRM2 receptors and agonist activity at human OPRM1 and CHRM2 receptors. The compound has been evaluated for binding affinity and inhibition of numerous targets, including KCNH2, ADRB1, SLC6A3, HTR2C, SLC6A4, ADRA2C, PTGS2, HTR3A, and MAOA, highlighting its extensive interaction profile.
Overall, Cinacalcet displays a wide array of biological activities across different assays, making it a compound of interest for further exploration in various therapeutic areas..
Note: Summary generated by AI. Data source: ChEMBL 